Frontiers in Immunology (Apr 2024)

Imatinib-induced dermatomyositis sine dermatitis - a rare case report

  • Augusto Silva,
  • Augusto Silva,
  • Vasco C. Romão,
  • Vasco C. Romão,
  • Raquel Campanilho-Marques,
  • Raquel Campanilho-Marques,
  • Raquel Campanilho-Marques

DOI
https://doi.org/10.3389/fimmu.2024.1398453
Journal volume & issue
Vol. 15

Abstract

Read online

Idiopathic Inflammatory Myopathies are rare conditions with several heterogeneous disease subtypes. They can range from limited muscle or skin involvement to severe, systemic, life-threatening disease. Although the etiology is unknown, some evidence suggests a role for external agents, particularly drugs. Herein, we present a case of a 71-year-old woman with chronic myeloid leukemia who developed imatinib-induced dermatomyositis sine dermatitis. The presentation was predominantly muscular, characterized by proximal muscle weakness and myalgia of the lower limbs, with positive anti-Mi2a antibodies. Spontaneous recovery was observed after drug discontinuation, without the need for immunosuppressive therapy. This is the first confirmed description of an imatinib-induced dermatomyositis sine dermatitis. It reflects the importance of a high awareness from rheumatologists and hematologists to accurately anticipate and identify similar situations.

Keywords